Genenta Science (GNTA) Competitors $4.24 -0.06 (-1.28%) As of 12:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNTA vs. ATYR, ATAI, AQST, CMPX, DBVT, CRVS, ACB, IMMP, AURA, and CGCShould you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include Atyr PHARMA (ATYR), Atai Life Sciences (ATAI), Aquestive Therapeutics (AQST), Compass Therapeutics (CMPX), DBV Technologies (DBVT), Corvus Pharmaceuticals (CRVS), Aurora Cannabis (ACB), Immutep (IMMP), Aura Biosciences (AURA), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry. Genenta Science vs. Atyr PHARMA Atai Life Sciences Aquestive Therapeutics Compass Therapeutics DBV Technologies Corvus Pharmaceuticals Aurora Cannabis Immutep Aura Biosciences Canopy Growth Genenta Science (NASDAQ:GNTA) and Atyr PHARMA (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations. Does the MarketBeat Community favor GNTA or ATYR? Atyr PHARMA received 7 more outperform votes than Genenta Science when rated by MarketBeat users. Likewise, 100.00% of users gave Atyr PHARMA an outperform vote while only 87.50% of users gave Genenta Science an outperform vote. CompanyUnderperformOutperformGenenta ScienceOutperform Votes787.50% Underperform Votes112.50%Atyr PHARMAOutperform Votes14100.00% Underperform VotesNo Votes Is GNTA or ATYR more profitable? Genenta Science's return on equity of 0.00% beat Atyr PHARMA's return on equity.Company Net Margins Return on Equity Return on Assets Genenta ScienceN/A N/A N/A Atyr PHARMA N/A -79.44%-59.16% Do analysts recommend GNTA or ATYR? Genenta Science presently has a consensus target price of $25.00, indicating a potential upside of 488.93%. Atyr PHARMA has a consensus target price of $18.60, indicating a potential upside of 400.67%. Given Genenta Science's higher possible upside, equities research analysts clearly believe Genenta Science is more favorable than Atyr PHARMA.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Atyr PHARMA 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Do insiders and institutionals hold more shares of GNTA or ATYR? 15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 61.7% of Atyr PHARMA shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by insiders. Comparatively, 3.7% of Atyr PHARMA shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media prefer GNTA or ATYR? In the previous week, Atyr PHARMA had 9 more articles in the media than Genenta Science. MarketBeat recorded 10 mentions for Atyr PHARMA and 1 mentions for Genenta Science. Atyr PHARMA's average media sentiment score of 0.76 beat Genenta Science's score of 0.00 indicating that Atyr PHARMA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genenta Science 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atyr PHARMA 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, GNTA or ATYR? Genenta Science has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Atyr PHARMA has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Which has better earnings and valuation, GNTA or ATYR? Genenta Science has higher earnings, but lower revenue than Atyr PHARMA. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenenta ScienceN/AN/A-$12.60MN/AN/AAtyr PHARMA$235K1,407.02-$50.39M-$0.81-4.59 SummaryAtyr PHARMA beats Genenta Science on 10 of the 15 factors compared between the two stocks. Get Genenta Science News Delivered to You Automatically Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNTA vs. The Competition Export to ExcelMetricGenenta ScienceBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.64M$2.92B$5.36B$8.40BDividend YieldN/A1.72%5.22%4.11%P/E RatioN/A30.7126.6219.74Price / SalesN/A398.27391.30117.36Price / CashN/A168.6838.2534.62Price / Book3.513.286.804.51Net Income-$12.60M-$72.17M$3.23B$248.18M7 Day Performance-0.93%4.13%4.02%1.07%1 Month Performance9.69%7.50%12.19%14.96%1 Year Performance40.21%-28.22%17.04%6.70% Genenta Science Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNTAGenenta Science1.5253 of 5 stars$4.25-1.3%$25.00+488.9%+43.4%$77.64MN/A0.007ATYRAtyr PHARMA2.8231 of 5 stars$3.24-1.2%$18.60+474.1%N/A$288.37M$235,000.00-3.4553News CoveragePositive NewsAnalyst ForecastATAIAtai Life Sciences2.3706 of 5 stars$1.44+3.6%$10.50+629.2%+18.5%$287.71M$308,000.00-1.7880News CoverageEarnings ReportAnalyst ForecastGap DownAQSTAquestive Therapeutics1.3228 of 5 stars$2.85+2.2%$10.67+274.3%-25.1%$283.07M$57.56M-6.33160News CoveragePositive NewsAnalyst RevisionGap UpCMPXCompass Therapeutics3.6721 of 5 stars$2.01+10.4%$13.13+553.0%+31.3%$277.95M$850,000.00-5.4320DBVTDBV Technologies3.0148 of 5 stars$10.13+3.1%$15.50+53.0%+52.4%$277.46M$15.73M-2.2580Gap DownCRVSCorvus Pharmaceuticals2.4338 of 5 stars$4.05-8.6%$16.33+303.3%+61.4%$276.08MN/A-4.3530Analyst ForecastHigh Trading VolumeACBAurora Cannabis0.4593 of 5 stars$5.06+4.3%N/A-27.8%$272.64M$320.81M101.221,340News CoverageIMMPImmutep1.5653 of 5 stars$1.87+1.1%$8.50+354.5%-35.2%$270.17M$5.14M0.002,021Gap DownAURAAura Biosciences2.4315 of 5 stars$5.35+2.3%$22.75+325.2%-16.5%$268.70MN/A-3.0950Earnings ReportInsider TradeGap UpCGCCanopy Growth0.8821 of 5 stars$1.46+11.5%$2.00+37.0%-82.5%$268.44M$276.75M-0.383,150Trending News Related Companies and Tools Related Companies Atyr PHARMA Competitors Atai Life Sciences Competitors Aquestive Therapeutics Competitors Compass Therapeutics Competitors DBV Technologies Competitors Corvus Pharmaceuticals Competitors Aurora Cannabis Competitors Immutep Competitors Aura Biosciences Competitors Canopy Growth Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNTA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genenta Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GNTA Stock Free GNTA Stock Alerts